Earlier today, Stellar Biotechnologies announced that its executive management team will be presenting at the following investor conferences:

• Marcum MicroCap Conference at the Grand Hyatt in New York City on May 29, 2014
• Stansberry & Associates Investment Research Conference at the AT&T Performing Arts Center, Dallas, TX on May 31, 2014

Frank Oakes, President and CEO of Stellar Biotechnologies, will deliver presentations at both events and members of Stellar’s executive team will be available for one-on-one meetings. A link to the Marcum conference webcast will be available in the Investor Relations section of the company’s website at http://ir.stellarbiotechnologies.com/events-calendar.

Stellar Biotechnologies is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, infectious diseases, and immune disorders) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology.

For more information on Stellar Biotechnologies, visit www.StellarBiotech.com

Let us hear your thoughts below: